Trials / Withdrawn
WithdrawnNCT04539730
Liposomal Bupivacaine in Adductor Canal Blocks (ACB)
Does the Addition of Liposomal Bupivacaine to the Adductor Canal Block Impact Narcotic Use After Primary Total Knee Arthroplasty: a Prospective, Blind Randomized Control Trial
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether liposomal bupivacaine is superior to normal bupivacaine in terms of providing better pain control postoperatively after total knee arthroplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liposomal bupivacaine | 266 mg or 20 ml Liposomal Bupivacaine injectable solution |
| PROCEDURE | Drug: SoC Ropivacaine | 0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine. |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-09-07
- Last updated
- 2021-12-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04539730. Inclusion in this directory is not an endorsement.